CLINICAL_TRIALS
trial_result
· 2022-03-14
Clinical Trial Update: A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis [Phase 2]
Summary
Phase 2 trial evaluating pimecrolimus (Elidel) for seborrheic dermatitis has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dermatology Specialists Research | Conditions: Seborrheic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2022-03-14